Zacks Rating on XOMA Corporation (XOMA)

XOMA Corporation (XOMA) : 1 brokerage houses believe that XOMA Corporation (XOMA) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on XOMA Corporation (XOMA). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 5 Wall Street Analysts endorse the stock as a Hold with a rating of 2.6.

XOMA Corporation (XOMA) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $3 and the lowest price target forecast is $1. The average forecast of all the analysts is $1.62 and the expected standard deviation is $1.2.


XOMA Corporation has dropped 1.75% in the last five trading days, however, the shares have posted positive gains of 8.96% in the last 4 weeks. XOMA Corporation has dropped 13.14% during the last 3-month period . Year-to-Date the stock performance stands at -54.94%. XOMA Corporation (NASDAQ:XOMA): stock turned positive on Tuesday. Though the stock opened at $0.58, the bulls momentum made the stock top out at $0.6083 level for the day. The stock recorded a low of $0.58 and closed the trading day at $0.5993, in the green by 0.32%. The total traded volume for the day was 251,238. The stock had closed at $0.5974 in the previous days trading.

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.